Department of Urology, Centre Hospitalier Auxerre, Auxerre, France.
World J Urol. 2012 Jun;30(3):419-26. doi: 10.1007/s00345-011-0756-2. Epub 2011 Sep 3.
This study's aim was to describe and evaluate outcomes of medical strategies used for lower urinary tract symptoms (LUTS) treatment in general practice and to assess impact of LUTS on patients' general health-related quality of life (HRQoL).
This cross-sectional observational study was conducted by French general practitioners. Eligible patients were males aged ≥50 years, diagnosed for at least one year and currently treated for LUTS due to benign prostatic hyperplasia (BPH). Several validated questionnaires were documented by patients to assess severity of LUTS (IPSS), specific quality of life (IPSS-Q8), impact of LUTS (BII), LUTS evolution (VNS) and general HRQoL (EQ-5D).
Among 1,098 patients included, 82.7% were treated with monotherapies and 17.3% with combinations. Mean treatment duration was 5.2 ± 3.2 years, and 47.2% of patients had at least one treatment modification since initiation. Patients reported diminished quality of life (IPSS-Q8 ≥3) (42.3%), persisting symptoms (IPSS-score ≥12) (35.5%), symptoms worsening (VNS-score ≤-1) (18.8%) and high bother (BII-score ≥9) (2.6%). Globally, 52.8% had at least one of these unsatisfactory outcomes. Regarding general HRQoL, mean EQ-5D utility significantly decreased with LUTS severity (mild: 0.90 ± 0.12; moderate: 0.81 ± 0.21; and severe symptoms: 0.73 ± 0.25; P < 0.001). As well, all five-dimensions of EQ-5D were significantly altered in patients with moderate-to-severe LUTS (<0.001), especially 'Pain/Discomfort' and 'Anxiety/Depression'. In multivariate analyses including age and comorbidities, EQ-5D utility index remained negatively associated with each additional unit in the IPSS-score.
This study shows that around half of BPH patients medically treated report unsatisfactory outcomes, suggesting consequential unmet medical needs in general practice. Also, moderate-to-severe LUTS significantly impact on general HRQoL.
本研究旨在描述和评估初级保健中用于治疗下尿路症状(LUTS)的医学策略的结果,并评估 LUTS 对患者总体健康相关生活质量(HRQoL)的影响。
这是一项由法国全科医生进行的横断面观察性研究。合格的患者为年龄≥50 岁的男性,至少诊断一年,目前因良性前列腺增生(BPH)接受 LUTS 治疗。患者使用多个经过验证的问卷评估 LUTS 的严重程度(IPSS)、特定的生活质量(IPSS-Q8)、LUTS 的影响(BII)、LUTS 的演变(VNS)和总体 HRQoL(EQ-5D)。
在纳入的 1098 名患者中,82.7%接受了单一疗法治疗,17.3%接受了联合疗法治疗。平均治疗持续时间为 5.2±3.2 年,自开始治疗以来,47.2%的患者至少有一次治疗调整。患者报告生活质量下降(IPSS-Q8≥3)(42.3%)、持续存在症状(IPSS 评分≥12)(35.5%)、症状恶化(VNS 评分≤-1)(18.8%)和高困扰(BII 评分≥9)(2.6%)。总体而言,52.8%的患者至少有一个不满意的结果。关于总体 HRQoL,随着 LUTS 严重程度的增加,平均 EQ-5D 效用显著下降(轻度:0.90±0.12;中度:0.81±0.21;重度症状:0.73±0.25;P<0.001)。同样,EQ-5D 的所有五个维度在中重度 LUTS 患者中均发生显著改变(<0.001),尤其是“疼痛/不适”和“焦虑/抑郁”。在包括年龄和合并症的多变量分析中,EQ-5D 效用指数与 IPSS 评分中每增加一个单位呈负相关。
本研究表明,大约一半接受药物治疗的 BPH 患者报告不满意的结果,这表明初级保健中存在未满足的医疗需求。此外,中重度 LUTS 显著影响总体 HRQoL。